Clinical Research Directory
Browse clinical research sites, groups, and studies.
Cyclophosphamide in the Treatment of Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes
Sponsor: Children's Hospital of Fudan University
Summary
This study evaluates the change of insulin resistance and glucose metabolism of patients with panniculitis associated acquired lipodystrophy syndrome and type 1 diabetes with the treatment of cyclophosphamide.
Official title: Cyclophosphamide in the Treatment of Panniculitis Associated Acquired Lipodystrophy Syndrome With Type 1 Diabetes
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2019-04-28
Completion Date
2030-05-31
Last Updated
2026-03-17
Healthy Volunteers
No
Conditions
Interventions
Cyclophosphamide
Admitted to the hospital every 4 weeks. Cyclophosphamide was intravenously instilled (500mg mg/m2 of BSA) after contraindications are excluded. ECG monitoring will be taken during the medication. A total of 6 treatments will be performed.
Locations (1)
Children's Hospital of Fudan University
Shanghai, Shanghai Municipality, China